

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions of claims in the subject application.

1. (currently amended) A combination for the treatment of neuropathic pain comprising an alpha-2-delta ligand selected from (3S,4S)-(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid; (3S,5R)-3-Amino-5-methyl-octanoic acid; and pharmaceutically acceptable salts thereof and an atypical antipsychotic, or selected from ziprasidone and pharmaceutically acceptable salts thereof.
2. (cancelled)
3. (cancelled)
4. (cancelled)
5. (cancelled)
6. (cancelled)
7. (currently amended) A pharmaceutical composition for the curative, prophylactic or palliative treatment of neuropathic pain comprising a therapeutically effective amount of a combination according to any one of claims 1-6, or pharmaceutically acceptable salts thereof Claim 1 and a suitable carrier or excipient.
8. (cancelled)
9. (cancelled)
10. (cancelled)

11. (cancelled)
12. (currently amended) A product containing and alpha-2-delta ligand selected from (3S,4S)-(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid; (3S,5R)-3-Amino-5-methyl-octanoic acid; and pharmaceutically acceptable salts thereof and an atypical antipsychotic, or selected from ziprasidone and pharmaceutically acceptable salts thereof, as a combined preparation for simultaneous, separate or sequential use in the treatment of neuropathic pain.